All members have the option of attending our various HTC-centric events which include:
Date: Thursday, October 12, 2023
Time: 1:00pm – 2:00pm ET
TITLE:
A Label Update on Rebinyn, (Coagulation Factor IX (Recombinant), GlycoPEGylated: FDA Approval for a Prophylaxis Indication for Persons with Hemophilia B
OBJECTIVE:
Provide a clinical review of Rebinyn that supports prophylaxis, on-demand and perioperative indication in adults and children
TARGET AUDIENCE:
All HTC Staff
SPEAKER:
Parin Chikani, PharmD, MBA
Medical Account Director, Novo Nordisk Inc
Parin Chikani, lives in the Chicagoland area and earned his Doctorate of Pharmacy degree from the University of Illinois at Chicago, College of Pharmacy and his MBA from Kellstadt Graduate School of Business. Before joining Novo Nordisk, Parin had been in the Pharmacy/Managed Care setting for over 15 years where he held many different roles and leadership positions within Pharmacy and Medical areas of the business. At Novo Nordisk, one of his roles and responsibilities is to ensure payors and clinicians are up-to-date on evidence based clinical and scientific information in the areas of Rare Diseases to help assist them with patient care.
